1. Home
  2. KYTX vs HNNA Comparison

KYTX vs HNNA Comparison

Compare KYTX & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYTX
  • HNNA
  • Stock Information
  • Founded
  • KYTX 2018
  • HNNA 1989
  • Country
  • KYTX United States
  • HNNA United States
  • Employees
  • KYTX N/A
  • HNNA N/A
  • Industry
  • KYTX
  • HNNA Investment Managers
  • Sector
  • KYTX
  • HNNA Finance
  • Exchange
  • KYTX NYSE
  • HNNA Nasdaq
  • Market Cap
  • KYTX 92.1M
  • HNNA 79.4M
  • IPO Year
  • KYTX 2024
  • HNNA N/A
  • Fundamental
  • Price
  • KYTX $2.55
  • HNNA $10.80
  • Analyst Decision
  • KYTX Strong Buy
  • HNNA
  • Analyst Count
  • KYTX 5
  • HNNA 0
  • Target Price
  • KYTX $19.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • KYTX 382.4K
  • HNNA 9.4K
  • Earning Date
  • KYTX 05-13-2025
  • HNNA 05-07-2025
  • Dividend Yield
  • KYTX N/A
  • HNNA 5.03%
  • EPS Growth
  • KYTX N/A
  • HNNA 83.55
  • EPS
  • KYTX N/A
  • HNNA 1.25
  • Revenue
  • KYTX N/A
  • HNNA $35,546,000.00
  • Revenue This Year
  • KYTX N/A
  • HNNA N/A
  • Revenue Next Year
  • KYTX N/A
  • HNNA N/A
  • P/E Ratio
  • KYTX N/A
  • HNNA $8.64
  • Revenue Growth
  • KYTX N/A
  • HNNA 41.94
  • 52 Week Low
  • KYTX $1.78
  • HNNA $6.94
  • 52 Week High
  • KYTX $16.64
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • KYTX 57.07
  • HNNA 55.42
  • Support Level
  • KYTX $2.43
  • HNNA $10.17
  • Resistance Level
  • KYTX $2.82
  • HNNA $11.10
  • Average True Range (ATR)
  • KYTX 0.23
  • HNNA 0.48
  • MACD
  • KYTX 0.04
  • HNNA 0.00
  • Stochastic Oscillator
  • KYTX 64.47
  • HNNA 71.15

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: